Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 3.0400 |
| Open | 3.0550 |
| Bid | 2.5200 x 1200 |
| Ask | 3.0900 x 800 |
| Day's range | 2.8041 - 3.1800 |
| 52-week range | 0.9550 - 3.3800 |
| Volume | |
| Avg. volume | 1,477,398 |
| Market cap | 68.56M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8860 |
| Earnings date | 13 Mar 2023 - 17 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.29 |
- Business Wire
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif., February 01, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.
- Zacks
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
